Shandong Xinhua Pharmaceutical Company Limited Class H (HK:0719) has released an update.
Shandong Xinhua Pharmaceutical’s subsidiary, Shandong Zibo Xincat Pharmaceutical, has received a Drug Registration Certificate from China’s National Medical Products Administration for its febuxostat tablets. The approval signifies compliance with domestic production standards and allows the company to proceed with manufacturing and sales. This development could enhance Shandong Xinhua’s market position in the pharmaceutical industry.
For further insights into HK:0719 stock, check out TipRanks’ Stock Analysis page.
